Skip to content
September 24, 2022

Equity.Guru

Investment information for the new generation

CMPS.Q

Interest in the psychedelic market is as high as Matt Gaetz and Joel Greenberg on a night out, but the accompanying FOMO has the potential to muddy the market,…
The psychedelics space is one of the hottest investment trips in the public markets today. Embryonic, wide open to possibility and with mounting scientific evidence of psychedelics’ healing properties,…
Revive Therapeutics (RVV.C) joined the AdvisorShares Psychedelics ETF (PSIL.NYSE) today, in time for its launch, according to a press release.   If you’re not entirely sure what an ETF…
“In business, cash is oxygen” – Gary Vaynerchuk   Psychedelics is a cash-intensive business. Earlier in the week, I wrote about how clinical trials alone cost companies tens, sometimes…
COMPASS Pathways (CMPS.Q) signed an MOU with South London and Maudsley NHS Foundation Trust (SLaM) and the Institute of Psychiatry, Psychology and Neuroscience (IoPPN) at King’s College London. The…
COMPASS Pathways (CMPS.Q) reported further results from a Phase I study on their COMP360 psilocybin conducted at King’s College London. The study was a randomized, double-blind, placebo-controlled study intended…
A study was published today in the New England Journal of Medicine which tested COMPASS Pathways’ (CMPS.Q) COMP360 psilocybin. The study is a phase II double-blind, randomized, controlled trial…
“Life is too short to be small.” – Tim Ferriss, The 4-Hour Workweek Every psychedelics company starts its investor deck off with a fact about the quickly changing regulatory…
Cut the kumbaya shit Throwing the words profit and psychedelic drugs into a sentence would have lead to awkward and confused looks 5 years ago. But we have come…
Pure Extracts is targeting the commercial cannabis and psychedelics sector, backed by deep extraction and production expertise….